Objective: A randomised and controlled experimental study was carried out to determine the effect of short and long series of treatment with recombinant human interferon-alpha-2b on surgically induced endometriosis in rats.
Study Design: Ninety-six Wistar adult female rats, which had undergone an autotransplant into the peritoneal cavity of four endometrial fragments measuring 4.5mm at the side, were randomly divided into three groups. One third of the animals were manipulated like the treated animals but were not given treatment and served as control (group C). Another third (group S) were treated with three doses (one every 48 h, 100,000 U per dose) of recombinant human interferon-alpha-2b (subcutaneous route), and the last third (group L) were treated with fifteen doses of interferon (100,000 U every 48 h).
Results: Before interferon was administered, there were no differences between groups in the average growth of experimental endometriosis per animal (17.3±6.7, 18.1±9.2, 16.4±5.6mm in groups C, S and L respectively). After the treatment, experimental endometriosis per animal was significantly smaller in the groups treated with interferon than in the control non-treated group (p<0.001), and in the group treated with 15 doses versus the group treated with 3 doses (p<0.05), (17.6±7.5, 14.0±9.5, 9.4±6.0mm in groups C, S, and L respectively). While the implants of the animals in the control group showed no change in size throughout the study (120 days) (+1.96% of variation), the mean size of the implants in the treated rats decreased, (22.7% with the short and 42.8% with the long series of treatment with interferon). Only one implant in group C (0.8%) disappeared, while this occurred in 27 cases (22.5%) in group S (p<0.001) and in 45 (37.5%) in group L (p<0.001 versus group C and p<0.05 versus group S).
Conclusion: The long series of treatment with human interferon-alpha-2b was more effective than the short one in reducing the size of surgically induced endometriosis in the peritoneal cavity of the rat.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejogrb.2012.11.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Network Meta-analysis of Chinese patent medicines combined with recombinant human interferon α-2b in treatment of cervical human papillomavirus infections].
Zhongguo Zhong Yao Za Zhi
December 2024
Xiyuan Hospital, China Academy of Chinese Medical Sciences Beijing 100091, China.
The study employed network Meta-analysis to evaluate the efficacy and safety of Chinese patent medicines combined with recombinant human interferon α-2b(interferon) in the treatment of cervical human papillomavirus(HPV) infections. The relevant randomized controlled trial(RCT) published from inception to May 8, 2024 were retrieved from CNKI, Wanfang, VIP, SinoMed, PubMed, Cochrane Library, EMbase, and Web of Science. The modified Jadad scale and the Cochrane risk of bias tool were used to evaluate the quality of the included studies, and RevMan 5.
View Article and Find Full Text PDFFedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial.
BMC Cancer
January 2025
Centre for Medical Education, Queen's University Belfast, Belfast City Hospital, Lisburn Road, Belfast, UK.
Background: Myelofibrosis (MF) is a clonal haematopoietic disease, with median overall survival for patients with primary MF only 6.5 years. The most frequent gene mutation found in patients is JAK2, causing constitutive activation of the kinase and activation of downstream signalling.
View Article and Find Full Text PDFPegylated interferon: the who, why, and how.
Hematology Am Soc Hematol Educ Program
December 2024
Hopital Saint-Louis, Paris Cité University, Inserm CIC 1427, Paris, France.
Interferon alpha (IFN-α) is a fascinating molecule with many biological properties yet to be fully understood. Among these properties, several have demonstrated usefulness for targeting malignant cells, including hematopoietic cells from patients with myeloproliferative neoplasms. Indeed, IFN-α has been used for decades across all myeloproliferative neoplasms, but only recently a new form, ropegIFN-α2b, was approved to treat patients with polycythemia vera.
View Article and Find Full Text PDFThe challenges of hepatic epithelioid hemangioendothelioma: the diagnosis and current treatments of a problematic tumor.
Orphanet J Rare Dis
November 2024
Department of Hepatobiliary and Pancreatic Surgery, China-Japan Friendship Hospital, Beijing, China.
Article Synopsis
- Hepatic epithelioid hemangioendothelioma (HEHE) is a rare malignant vascular tumor with different types that affect prognosis and treatment plans, posing unique clinical challenges for diagnosis and therapy.
- The unclear causes of HEHE complicate its diagnosis, which often relies on tissue biopsy but encounters issues due to late identification and misdiagnosis, lacking specific treatment guidelines.
- Surgical options are the primary recommendation for better survival outcomes, but limited patient eligibility and donor organ shortages for liver transplants create obstacles; non-surgical treatments show promise but have limited research backing.
Clinical efficacy of recombinant human interferon α-2b gel combined with LEEP conization in treating cervical intraepithelial neoplasia with comorbid high-risk HPV infection.
Am J Transl Res
October 2024
Department of Obstetrics and Gynecology, Hanchuan Hospital of Traditional Chinese Medicine Hanchuan 432300, Hubei, China.
Objective: To evaluate the clinical efficacy of recombinant human interferon α-2b (rHuINF α-2b) gel combined with loop electrosurgical excision procedure (LEEP) conization in treating cervical intraepithelial neoplasia (CIN) with comorbid high-risk human papillomavirus (HR-HPV) infection.
Methods: A retrospective analysis was conducted on the clinical data of 202 CIN patients with HR-HPV infection who were treated at Wuhan Yaxin General Hospital between July 2021 and February 2024. Among these patients, 106 received treatment with rHuINF α-2b gel combined with LEEP conization (study group), and the other 96 were treated with LEEP conization alone (control group).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!